{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:25:34Z","timestamp":1759332334208,"version":"3.40.5"},"reference-count":166,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Cystic fibrosis (CF) is a genetic disease that results in dysfunction of the CF transmembrane conductance regulator (CFTR) protein, which is a chloride and bicarbonate channel expressed in the apical portion of epithelial cells of various organs. Dysfunction of that protein results in diverse clinical manifestations, primarily involving the respiratory and gastrointestinal systems, impairing quality of life and reducing life expectancy. Although CF is still an incurable pathology, the therapeutic and prognostic perspectives are now totally different and much more favorable. The purpose of these guidelines is to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of the pulmonary symptoms of CF in Brazil. Questions in the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) format were employed to address aspects related to the use of modulators of this protein (ivacaftor, lumacaftor+ivacaftor, and tezacaftor+ivacaftor), use of dornase alfa, eradication therapy and chronic suppression of Pseudomonas aeruginosa, and eradication of methicillin-resistant Staphylococcus aureus and Burkholderia cepacia complex. To formulate the PICO questions, a group of Brazilian specialists was assembled and a systematic review was carried out on the themes, with meta-analysis when applicable. The results obtained were analyzed in terms of the strength of the evidence compiled, the recommendations being devised by employing the GRADE approach. We believe that these guidelines represent a major advance to be incorporated into the approach to patients with CF, mainly aiming to favor the management of the disease, and could become an auxiliary tool in the definition of public policies related to CF.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20230040","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:52:03Z","timestamp":1683042723000},"page":"e20230040","source":"Crossref","is-referenced-by-count":3,"title":["Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9399-5275","authenticated-orcid":false,"given":"Rodrigo","family":"Abensur Athanazio1","sequence":"first","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-2759","authenticated-orcid":false,"given":"Suzana","family":"Erico Tanni8","sequence":"additional","affiliation":[{"name":"8. Faculdade de Medicina de Botucatu, Universidade Estadual Paulista Julio de Mesquita Filho \u2013 UNESP \u2013 Botucatu (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-1384","authenticated-orcid":false,"given":"Juliana","family":"Ferreira1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9774-9135","authenticated-orcid":false,"given":"Paulo","family":"de Tarso Roth Dalcin3,4","sequence":"additional","affiliation":[{"name":"3. Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias Pneumol\u00f3gicas, Universidade Federal do Rio Grande do Sul \u2013 UFRGS \u2013 Porto Alegre (RS) Brasil. 4. Servi\u00e7o de Pneumologia, Hospital de Cl\u00ednicas de Porto Alegre \u2013 HCPA \u2013 Universidade Federal do Rio Grande do Sul \u2013 UFRGS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-3135","authenticated-orcid":false,"given":"Marcelo","family":"B de Fuccio5","sequence":"additional","affiliation":[{"name":"5. Hospital J\u00falia Kubitschek, Funda\u00e7\u00e3o Hospitalar do Estado de Minas Gerais \u2013 FHEMIG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-7139","authenticated-orcid":false,"given":"Concetta","family":"Esposito6","sequence":"additional","affiliation":[{"name":"6. Hospital Nereu Ramos, Florian\u00f3polis (SC) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-2107","authenticated-orcid":false,"given":"Mariane","family":"Gon\u00e7alves Martynychen Canan7","sequence":"additional","affiliation":[{"name":"7. Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba (PR) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-5211","authenticated-orcid":false,"given":"Liana","family":"Sousa Coelho8","sequence":"additional","affiliation":[{"name":"8. Faculdade de Medicina de Botucatu, Universidade Estadual Paulista Julio de Mesquita Filho \u2013 UNESP \u2013 Botucatu (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1741-2952","authenticated-orcid":false,"given":"M\u00f4nica","family":"de C\u00e1ssia Firmida9","sequence":"additional","affiliation":[{"name":"9. Universidade do Estado do Rio de Janeiro, Rio de Janeiro (RJ) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-5940","authenticated-orcid":false,"given":"Marina","family":"Buarque de Almeida2","sequence":"additional","affiliation":[{"name":"2. Unidade de Pneumologia, Instituto da Crian\u00e7a, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0252-7570","authenticated-orcid":false,"given":"Paulo","family":"Jos\u00e9 Cauduro Marostica10","sequence":"additional","affiliation":[{"name":"10. Unidade de Pneumologia Infantil, Hospital de Cl\u00ednicas de Porto Alegre \u2013 HCPA \u2013 Universidade Federal do Rio Grande do Sul \u2013 UFRGS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5595-351X","authenticated-orcid":false,"given":"Luciana","family":"de Freitas Velloso Monte11,12","sequence":"additional","affiliation":[{"name":"11. Hospital da Crian\u00e7a de Bras\u00edlia Jos\u00e9 Alencar, Bras\u00edlia (DF) Brasil. 12. Universidade Cat\u00f3lica de Bras\u00edlia, Bras\u00edlia (DF) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-8483","authenticated-orcid":false,"given":"Edna","family":"L\u00facia Souza13","sequence":"additional","affiliation":[{"name":"13. Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador (BA) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-5456","authenticated-orcid":false,"given":"Leonardo","family":"Araujo Pinto14","sequence":"additional","affiliation":[{"name":"14. Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6741-1320","authenticated-orcid":false,"given":"Samia","family":"Zahi Rached1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-9374","authenticated-orcid":false,"given":"Ver\u00f4nica","family":"Stasiak Bednarczuk de Oliveira7,15","sequence":"additional","affiliation":[{"name":"7. Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba (PR) Brasil. 15. Unidos Pela Vida \u2013 Instituto Brasileiro de Aten\u00e7\u00e3o \u00e0 Fibrose C\u00edstica, Curitiba (PR) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-1997","authenticated-orcid":false,"given":"Luiz","family":"Vicente Ribeiro Ferreira da Silva Filho2","sequence":"additional","affiliation":[{"name":"2. Unidade de Pneumologia, Instituto da Crian\u00e7a, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.            Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010. https:\/\/doi.org\/10.1038\/nrdp.2015.10","DOI":"10.1038\/nrdp.2015.10"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.            Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective [published correction appears in Lancet Respir Med. 2019 Dec;7(12):e40]. Lancet Respir Med. 2020;8(1):65-124. https:\/\/doi.org\/10.1016\/S2213-2600(19)30337-6","DOI":"10.1016\/s2213-2600(19)30408-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Elborn JS. CFTR Modulators: Deciding What Is Best for Individuals in an Era of Precision Medicine. Ann Am Thorac Soc. 2018;15(3):298-300. https:\/\/doi.org\/10.1513\/AnnalsATS.201712-951ED","DOI":"10.1513\/annalsats.201712-951ed"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            Habib AR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep. 2019;9(1):7234. https:\/\/doi.org\/10.1038\/s41598-019-43652-2","DOI":"10.1038\/s41598-019-43652-2"},{"key":"ref4","unstructured":"5.            Flume PA, Robinson KA, O\u2019Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522-537."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689. https:\/\/doi.org\/10.1164\/rccm.201207-1160OE","DOI":"10.1164\/rccm.201207-1160oe"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.            Athanazio RA, Silva Filho LVRF, Vergara AA, Ribeiro AF, Riedi CA, Procianoy EDFA, et al. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol. 2017;43(3):219-245. https:\/\/doi.org\/10.1590\/s1806-37562017000000065","DOI":"10.1590\/s1806-37562017000000065"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.            Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-178. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.006","DOI":"10.1016\/j.jcf.2018.02.006"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.            Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol. 2017;52(S48):S4-S14. https:\/\/doi.org\/10.1002\/ppul.23773","DOI":"10.1002\/ppul.23773"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.          Chaudary N. Triplet CFTR modulators: future prospects for treatment of cystic fibrosis. Ther Clin Risk Manag. 2018;14:2375-2383. https:\/\/doi.org\/10.2147\/TCRM.S147164","DOI":"10.2147\/tcrm.s147164"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672. https:\/\/doi.org\/10.1056\/NEJMoa1105185","DOI":"10.1056\/nejmoa1105185"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.          Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-231. https:\/\/doi.org\/10.1056\/NEJMoa1409547","DOI":"10.1056\/nejmoa1409547"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017;377(21):2013-2023. https:\/\/doi.org\/10.1056\/NEJMoa1709846","DOI":"10.1056\/nejmoa1709846"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.          Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, et al. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med. 2017;377(21):2024-2035. https:\/\/doi.org\/10.1056\/NEJMoa1709847","DOI":"10.1056\/nejmoa1709847"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.          Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet. 2019;394(10212):1940-1948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","DOI":"10.1016\/s0140-6736(19)32597-8"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.          Middleton PG, Mall MA, Drev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","DOI":"10.1056\/nejmoa1908639"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.          Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-642. https:\/\/doi.org\/10.1056\/NEJM199409083311003","DOI":"10.1056\/nejm199409083311003"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.          Goss CH, MacNeill SJ, Quinton HB, Marshall BC, Elbert A, Knapp EA, et al. Children and young adults with CF in the USA have better lung function compared with the UK. Thorax. 2015;70(3):229-236. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205718","DOI":"10.1136\/thoraxjnl-2014-205718"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.          Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2021;3(3):CD001127. https:\/\/doi.org\/10.1002\/14651858.CD001127.pub5","DOI":"10.1002\/14651858.cd001127.pub5"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.          Grupo Brasileiro de Estudos de Fibrose C\u00edstica (GBEFC) [homepage on the Internet]. Curitiba: GBEFC; c2023 [cited 2023 Feb 4]. Registro Brasileiro de Fibrose C\u00edstica 2019. [Adobe Acrobat document, 61p.]. Available from: http:\/\/portalgbefc.org.br\/ckfinder\/userfiles\/files\/REBRAFC_2019.pdf","DOI":"10.51161\/iii-conbrasau\/11725"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.          Mogayzel PJ Jr, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640-1650. https:\/\/doi.org\/10.1513\/AnnalsATS.201404-166OC","DOI":"10.1513\/annalsats.201404-166oc"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.          Lo DK, Muhlebach MS, Smyth AR. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev. 2018;7(7):CD009650. https:\/\/doi.org\/10.1002\/14651858.CD009650.pub4","DOI":"10.1002\/14651858.cd009650.pub4"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.          Garcia BA, Carden JL, Goodwin DL, Smith TA, Gaggar A, Leon K, et al. Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients. BMC Pulm Med. 2018;18(1):35. https:\/\/doi.org\/10.1186\/s12890-018-0594-8","DOI":"10.1186\/s12890-018-0594-8"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.          Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012;47(6):523-533. https:\/\/doi.org\/10.1002\/ppul.22546","DOI":"10.1002\/ppul.22546"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.          Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","DOI":"10.1136\/bmj.39489.470347.ad"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.          Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ; et al. What is \u201cquality of evidence\u201d and why is it important to clinicians?. BMJ. 2008;336(7651):995-998. https:\/\/doi.org\/10.1136\/bmj.39490.551019.BE","DOI":"10.1136\/bmj.39490.551019.be"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.          Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations [published correction appears in BMJ. 2008 Jun 21;336(7658): doi:10.1136\/bmj.a402]. BMJ. 2008;336(7652):1049-1051. https:\/\/doi.org\/10.1136\/bmj.a402","DOI":"10.1136\/bmj.39493.646875.ae"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.          Abou Alaiwa MH, Launspach JL, Grogan B, Carter S, Zabner J, Stoltz DA, et al. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis. JCI Insight. 2018;3(15):e121468. https:\/\/doi.org\/10.1172\/jci.insight.121468","DOI":"10.1172\/jci.insight.121468"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.          Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991-2003. https:\/\/doi.org\/10.1056\/NEJMoa0909825","DOI":"10.1517\/13543784.2011.554823"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.          Barry PJ, Plant BJ, Nair A, Bicknell S, Simmonds NJ, Bell NJ, et al. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest. 2014;146(1):152-158. https:\/\/doi.org\/10.1378\/chest.13-2397","DOI":"10.1378\/chest.13-2397"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.          Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018;73(8):731-740. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210394","DOI":"10.1136\/thoraxjnl-2017-210394"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.          Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, et al. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Dig Dis Sci. 2016;61(1):198-207. https:\/\/doi.org\/10.1007\/s10620-015-3834-2","DOI":"10.1007\/s10620-015-3834-2"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.          Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219-1225. https:\/\/doi.org\/10.1164\/rccm.201301-0153OC","DOI":"10.1164\/rccm.201301-0153oc"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.          De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674-680. https:\/\/doi.org\/10.1016\/j.jcf.2014.09.005","DOI":"10.1016\/j.jcf.2014.09.005"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.          Donaldson SH, Laube BL, Corcoran TE, Bhambhvani P, Zeman K, Ceppe A, et al. Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight. 2018;3(24):e122695. https:\/\/doi.org\/10.1172\/jci.insight.122695","DOI":"10.1172\/jci.insight.122695"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.          Edgeworth D, Keating D, Ellis M, Button B, Williams E, Clark D, et al. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Clin Sci (Lond). 2017;131(15):2037-2045. https:\/\/doi.org\/10.1042\/CS20170995","DOI":"10.1042\/cs20170995"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.          Gomez-Pastrana D, Nwokoro C, McLean M, Brown S, Christiansen N, Pao CS. Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation [Article in Spanish]. An Pediatr (Engl Ed). 2019;90(3):148-156. https:\/\/doi.org\/10.1016\/j.anpedi.2018.05.022","DOI":"10.1016\/j.anpede.2018.05.003"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.          Guerra L, D\u2019Oria S, Favia M, Castellani S, Santostasi T, Polizzi AM, et al. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy. Pediatr Pulmonol. 2017;52(7):900-908. https:\/\/doi.org\/10.1002\/ppul.23712","DOI":"10.1002\/ppul.23712"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.          Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, et al. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros. 2019;18(1):102-109. https:\/\/doi.org\/10.1016\/j.jcf.2018.04.004","DOI":"10.1016\/j.jcf.2018.04.004"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40.          Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, et al. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Ann Am Thorac Soc. 2020;17(2):212-220. https:\/\/doi.org\/10.1513\/AnnalsATS.201907-493OC","DOI":"10.1513\/annalsats.201907-493oc"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.          Hebestreit H, Sauer-Heilborn A, Fischer R, K\u00e4ding M, Mainz JG. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation. J Cyst Fibros. 2013;12(6):599-603. https:\/\/doi.org\/10.1016\/j.jcf.2013.05.006","DOI":"10.1016\/j.jcf.2013.05.006"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42.          Hubert D, Dehillotte C, Munck A, David V, Baek J, Mely L, et al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting. J Cyst Fibros. 2018;17(1):89-95. https:\/\/doi.org\/10.1016\/j.jcf.2017.07.001","DOI":"10.1016\/j.jcf.2017.07.001"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.          McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014;2(11):902-910. https:\/\/doi.org\/10.1016\/S2213-2600(14)70218-8","DOI":"10.1016\/s2213-2600(14)70218-8"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.          Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(7):524-533. https:\/\/doi.org\/10.1016\/S2213-2600(15)00201-5","DOI":"10.1016\/s2213-2600(15)00201-5"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45.          Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione B, et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015;13:93. https:\/\/doi.org\/10.1186\/s12955-015-0293-6","DOI":"10.1186\/s12955-015-0293-6"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.          Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M, et al. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor. Chest. 2018;153(2):395-403. https:\/\/doi.org\/10.1016\/j.chest.2017.10.005","DOI":"10.1016\/j.chest.2017.10.005"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47.          Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study [published correction appears in Lancet Respir Med. 2018 Jul;6(7):e35] [published correction appears in Lancet Respir Med. 2019 Apr;7(4):e15]. Lancet Respir Med. 2018;6(7):545-553. https:\/\/doi.org\/10.1016\/S2213-2600(18)30202-9","DOI":"10.1016\/s2213-2600(19)30408-4"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48.          Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175-184. https:\/\/doi.org\/10.1164\/rccm.201404-0703OC","DOI":"10.1164\/rccm.201404-0703oc"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49.          Salvatore D, Carnovale V, Iacotucci P, Braggion C, Castellani C, Cimino G, et al. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations. Pediatr Pulmonol. 2019;54(9):1398-1403. https:\/\/doi.org\/10.1002\/ppul.24424","DOI":"10.1002\/ppul.24424"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50.          Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. J Cyst Fibros. 2015;14(1):84-89. https:\/\/doi.org\/10.1016\/j.jcf.2014.06.011","DOI":"10.1016\/j.jcf.2014.06.011"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51.          Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Clin Otolaryngol. 2015;40(1):16-21. https:\/\/doi.org\/10.1111\/coa.12310","DOI":"10.1111\/coa.12310"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52.          Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations. J Pediatr. 2018;201:229-237.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2018.05.018","DOI":"10.1016\/j.jpeds.2018.05.018"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53.          Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM; VX11-770-901 investigators. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. J Cyst Fibros. 2016;15(1):116-122. https:\/\/doi.org\/10.1016\/j.jcf.2015.01.008","DOI":"10.1016\/j.jcf.2015.01.008"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54.          van de Peppel IP, Doktorova M, Berkers G, de Jonge HR, Houwen RHJ, Verkade HJ, et al. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. J Cyst Fibros. 2019;18(2):286-293. https:\/\/doi.org\/10.1016\/j.jcf.2018.09.001","DOI":"10.1016\/j.jcf.2018.09.001"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"55.          Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2020;19(1):68-79. https:\/\/doi.org\/10.1016\/j.jcf.2019.05.015","DOI":"10.1016\/j.jcf.2019.05.015"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56.          Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5(2):107-118. https:\/\/doi.org\/10.1016\/S2213-2600(16)30427-1","DOI":"10.1016\/s2213-2600(16)30427-1"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57.          Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial [published correction appears in Lancet Respir Med. 2017 Aug;5(8):e28]. Lancet Respir Med. 2017;5(7):557-567. https:\/\/doi.org\/10.1016\/S2213-2600(17)30215-1","DOI":"10.1016\/s1569-1993(17)30234-5"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"58.          Burgel PR, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al. Real-Life Safety and Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. Am J Respir Crit Care Med. 2020;201(2):188-197. https:\/\/doi.org\/10.1164\/rccm.201906-1227OC","DOI":"10.1016\/s1569-1993(19)30558-2"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"59.          Diab-C\u00e1ceres L, Gir\u00f3n-Moreno RM, Pastor-Sanz MT, Quintana-Gallego E, Delgado-Pecell\u00edn I, Blanco-Aparicio M, et al. Compassionate Use of Lumacaftor\/Ivacaftor in Cystic Fibrosis: Spanish Experience. Arch Bronconeumol (Engl Ed). 2018;54(12):614-618. https:\/\/doi.org\/10.1016\/j.arbr.2018.05.020","DOI":"10.1016\/j.arbres.2018.05.004"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60.          Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, et al. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Am J Respir Crit Care Med. 2018;197(11):1433-1442. https:\/\/doi.org\/10.1164\/rccm.201710-1983OC","DOI":"10.1164\/rccm.201710-1983oc"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61.          Hubert D, Chiron R, Camara B, Grenet D, Pr\u00e9votat A, Bassinet L, et al. Real-life initiation of lumacaftor\/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros. 2017;16(3):388-391. https:\/\/doi.org\/10.1016\/j.jcf.2017.03.003","DOI":"10.1016\/j.jcf.2017.03.003"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"62.          Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A, et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor\/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662-1666. https:\/\/doi.org\/10.1513\/AnnalsATS.201701-058OC","DOI":"10.1513\/annalsats.201701-058oc"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63.          Masson A, Schneider-Futschik EK, Baatallah N, Nguyen-Khoa T, Girodon E, Hatton A, et al. Predictive factors for lumacaftor\/ivacaftor clinical response. J Cyst Fibros. 2019;18(3):368-374. https:\/\/doi.org\/10.1016\/j.jcf.2018.12.011","DOI":"10.1016\/j.jcf.2018.12.011"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64.          McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, et al. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019;7(4):325-335. https:\/\/doi.org\/10.1016\/S2213-2600(18)30460-0","DOI":"10.1016\/s2213-2600(18)30460-0"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65.          Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; et al. Lumacaftor\/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2017;195(7):912-920. https:\/\/doi.org\/10.1164\/rccm.201608-1754OC","DOI":"10.1164\/rccm.201608-1754oc"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"66.          Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, B\u00fcrgi U, et al. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results. Swiss Med Wkly. 2018;148:w14593. https:\/\/doi.org\/10.4414\/smw.2018.14593","DOI":"10.4414\/smw.2018.14593"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67.          Taylor-Cousar JL, Jain M, Barto TL, Haddad T, Atkinson J, Tian S, et al. Lumacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018;17(2):228-235. https:\/\/doi.org\/10.1016\/j.jcf.2017.09.012","DOI":"10.1016\/j.jcf.2017.09.012"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"68.          Tesell MA, Alper CJ, Bacon R, Greenwood BC, Lenz K, Jeffrey PL, et al. Effect of Lumacaftor\/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population. J Manag Care Spec Pharm. 2019;25(9):1021-1025. https:\/\/doi.org\/10.18553\/jmcp.2019.25.9.1021","DOI":"10.18553\/jmcp.2019.25.9.1021"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"69.          Wark PAB, Cookson K, Thiruchelvam T, Brannan J, Dorahy DJ. Lumacaftor\/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction. BMC Pulm Med. 2019;19(1):106. https:\/\/doi.org\/10.1186\/s12890-019-0866-y","DOI":"10.1186\/s12890-019-0866-y"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"70.          Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et  al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32(4):277-287. https:\/\/doi.org\/10.1002\/ppul.2009.abs","DOI":"10.1002\/ppul.2009.abs"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"71.          Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros. 2017;16(3):395-400. https:\/\/doi.org\/10.1016\/j.jcf.2017.01.007","DOI":"10.1016\/j.jcf.2017.01.007"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"72.          Claude F, Rochat I, Hafen GM. No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis. BMC Res Notes. 2019;12(1):115. https:\/\/doi.org\/10.1186\/s13104-019-4157-8","DOI":"10.1186\/s13104-019-4157-8"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"73.          Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, et al. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. J Cyst Fibros. 2021;20(1):68-77. https:\/\/doi.org\/10.1016\/j.jcf.2020.07.023","DOI":"10.1016\/j.jcf.2020.07.023"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"74.          Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, et al. Tezacaftor\/Ivacaftor in Subjects with Cystic Fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR. Am J Respir Crit Care Med. 2018;197(2):214-224. https:\/\/doi.org\/10.1164\/rccm.201704-0717OC","DOI":"10.1164\/rccm.201704-0717oc"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"75.          Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, et al. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11\u202fyears with cystic fibrosis. J Cyst Fibros. 2019;18(5):708-713. https:\/\/doi.org\/10.1016\/j.jcf.2019.06.009","DOI":"10.1016\/j.jcf.2019.06.009"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"76.          Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100. https:\/\/doi.org\/10.1002\/ppul.10127","DOI":"10.1002\/ppul.10127"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"77.          Cohen-Cymberknoh M, Gilead N, Gartner S, Rovira S, Blau H, Mussaffi H, et al. Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis. J Cyst Fibros. 2016;15(6):776-782. https:\/\/doi.org\/10.1016\/j.jcf.2016.04.006","DOI":"10.1016\/j.jcf.2016.04.006"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"78.          Emiralioglu N, Yalcin E, Meral A, Sener B, Dogru D, Ozcelik U, et al. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis. J Clin Pharm Ther. 2016;41(4):419-423. https:\/\/doi.org\/10.1111\/jcpt.12407","DOI":"10.1111\/jcpt.12407"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.          Frederiksen B, Koch C, H\u00f8iby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23(5):330-335. https:\/\/doi.org\/10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O"},{"key":"ref79","unstructured":"80.          Giugno H, Casta\u00f1os C, Lubatti A, Pinheiro JL, Hern\u00e1ndez C, Gonz\u00e1lez Pena H. Early antibiotic treatment for eradication of initial infection by Pseudomonas aeruginosa in patients with cystic fibrosis. Arch Argent Pediatr. 2010;108(2):141-147. https:\/\/doi.org\/10.1590\/S0325-00752010000200009"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"81.          Hewer SCL, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, et al. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respir Med. 2020;8(10):975-986. https:\/\/doi.org\/10.1016\/S2213-2600(20)30331-3","DOI":"10.1016\/s2213-2600(20)30331-3"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"82.          Kenny SL, Shaw TD, Downey DG, Moore JE, Rendall JC, Elborn JS. Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis. BMJ Open Respir Res. 2014;1(1):e000021. https:\/\/doi.org\/10.1136\/bmjresp-2014-000021","DOI":"10.1136\/bmjresp-2014-000021"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"83.          Mayer-Hamblett N, Kloster M, Rosenfeld M, Gibson RL, Retsch-Bogart GZ, Emerson J, et al. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis. Clin Infect Dis. 2015;61(5):707-715. https:\/\/doi.org\/10.1093\/cid\/civ377","DOI":"10.1093\/cid\/civ377"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"84.          Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2013;12(1):29-34. https:\/\/doi.org\/10.1016\/j.jcf.2012.06.001","DOI":"10.1016\/j.jcf.2012.06.001"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"85.          Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4):286-291. https:\/\/doi.org\/10.1136\/thx.2009.121657","DOI":"10.1136\/thx.2009.121657"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"86.          Ratjen F, Moeller A, McKinney ML, Asherova I, Alon N, Maykut R, et al. Eradication of early P. aeruginosa infection in children <7\u202fyears of age with cystic fibrosis: The early study. J Cyst Fibros. 2019;18(1):78-85. https:\/\/doi.org\/10.1016\/j.jcf.2018.04.002","DOI":"10.1016\/j.jcf.2018.04.002"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"87.          Taccetti G, Campana S, Festini F, Mascherini M, D\u00f6ring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26(3):458-461. https:\/\/doi.org\/10.1183\/09031936.05.00009605","DOI":"10.1183\/09031936.05.00009605"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"88.          Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax. 2012;67(10):853-859. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-200832","DOI":"10.1136\/thoraxjnl-2011-200832"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"89.          Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(9):847-856. https:\/\/doi.org\/10.1001\/archpediatrics.2011.136","DOI":"10.1016\/s1569-1993(10)60210-x"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"90.          Valerius NH, Koch C, H\u00f8iby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725-726. https:\/\/doi.org\/10.1016\/0140-6736(91)91446-2","DOI":"10.1016\/0140-6736(91)91446-2"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.          Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, D\u00f6ring G, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol. 1998;25(2):88-92. https:\/\/doi.org\/10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"92.          Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34. https:\/\/doi.org\/10.1016\/S1569-1993(02)00141-8","DOI":"10.1016\/s1569-1993(02)00141-8"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"93.          Lund-Palau H, Turnbull AR, Bush A, Bardin E, Cameron L, Soren O, et al. Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Rev Respir Med. 2016;10(6):685-697. https:\/\/doi.org\/10.1080\/17476348.2016.1177460","DOI":"10.1080\/17476348.2016.1177460"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"94.          Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, et al. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016;15(4):495-502. https:\/\/doi.org\/10.1016\/j.jcf.2015.12.004","DOI":"10.1016\/j.jcf.2015.12.004"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"95.          Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013;12(2):130-140. https:\/\/doi.org\/10.1016\/j.jcf.2012.07.006","DOI":"10.1016\/j.jcf.2012.07.006"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"96.          Chuchalin A, Csisz\u00e9r E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs. 2007;9 Suppl 1:21-31. https:\/\/doi.org\/10.2165\/00148581-200709001-00004","DOI":"10.2165\/00148581-200709001-00004"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"97.          Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ; et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183(11):1510-1516. https:\/\/doi.org\/10.1164\/rccm.201008-1293OC","DOI":"10.1164\/rccm.201008-1293oc"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"98.          Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981;2(8256):1137-1139. https:\/\/doi.org\/10.1016\/S0140-6736(81)90588-2","DOI":"10.1016\/s0140-6736(81)90588-2"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"99.          Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658-664. https:\/\/doi.org\/10.1183\/09031936.02.00248102","DOI":"10.1183\/09031936.02.00248102"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"100.        Jensen T, Pedersen SS, Garne S, Heilmann C, H\u00f8iby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987;19(6):831-838. https:\/\/doi.org\/10.1093\/jac\/19.6.831","DOI":"10.1093\/jac\/19.6.831"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"101.        Konstan MW, Geller DE, Mini\u0107 P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol. 2011;46(3):230-238. https:\/\/doi.org\/10.1002\/ppul.21356","DOI":"10.1002\/ppul.21356"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"102.        Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011;10(1):54-61. https:\/\/doi.org\/10.1016\/j.jcf.2010.10.003","DOI":"10.1016\/j.jcf.2010.10.003"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"103.        Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J. 1984;20(1):43-45. https:\/\/doi.org\/10.1111\/j.1440-1754.1984.tb00035.x","DOI":"10.1111\/j.1440-1754.1984.tb00035.x"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"104.        Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs. 2007;9 Suppl 1:11-20. https:\/\/doi.org\/10.2165\/00148581-200709001-00003","DOI":"10.2165\/00148581-200709001-00003"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"105.        MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42-48. https:\/\/doi.org\/10.1002\/ppul.1950070110","DOI":"10.1002\/ppul.1950070110"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"106.        McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-928. https:\/\/doi.org\/10.1164\/rccm.200712-1804OC","DOI":"10.1164\/rccm.200712-1804oc"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"107.        Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 2001;120(3 Suppl):107S-113S. https:\/\/doi.org\/10.1378\/chest.120.3_suppl.107S","DOI":"10.1378\/chest.120.3_suppl.107s"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"108.        Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38(4):314-320. https:\/\/doi.org\/10.1002\/ppul.20097","DOI":"10.1002\/ppul.20097"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"109.        Nasr SZ, Sakmar E, Christodoulou E, Eckhardt BP, Streetman DS, Strouse PJ. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatr Pulmonol. 2010;45(5):440-449. https:\/\/doi.org\/10.1002\/ppul.21188","DOI":"10.1002\/ppul.21188"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"110.        Nikolaizik WH, Vietzke D, Ratjen F. A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. Can Respir J. 2008;15(5):259-262. https:\/\/doi.org\/10.1155\/2008\/202464","DOI":"10.1155\/2008\/202464"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"111.        Quintana-Gallego E, Lopez-Campos JL, Calero C, Dapena FJ. Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients [Article in Spanish]. Med Clin (Barc). 2014;142(2):59-63. https:\/\/doi.org\/10.1016\/j.medcli.2012.11.026","DOI":"10.1016\/j.medcli.2012.11.026"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"112.        Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30. https:\/\/doi.org\/10.1056\/NEJM199901073400104","DOI":"10.1056\/nejm199901073400104"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"113.        Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232. https:\/\/doi.org\/10.1378\/chest.08-1421","DOI":"10.1378\/chest.08-1421"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"114.        Schuster A, Haliburn C, D\u00f6ring G, Goldman MH; Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68(4):344-350. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-202059","DOI":"10.1136\/thoraxjnl-2012-202059"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"115.        Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest. 1987;81(3):272-279. https:\/\/doi.org\/10.1016\/0007-0971(87)90161-6","DOI":"10.1016\/0007-0971(87)90161-6"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"116.        Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015;14(4):507-514. https:\/\/doi.org\/10.1016\/j.jcf.2014.12.013","DOI":"10.1016\/j.jcf.2014.12.013"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"117.        Toukan Y, Gur M, Hakim FH, Geffen Y, Bar-Yoseph R, Nir V, et al. Intermittent inhaled tobramycin and systemic cytokines response in CF patients with Pseudomonas aeruginosa. Clin Invest Med. 2018;41(3):E136-E143. https:\/\/doi.org\/10.25011\/cim.v41i3.30792","DOI":"10.25011\/cim.v41i3.30792"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"118.        Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004;3(1):23-28. https:\/\/doi.org\/10.1016\/j.jcf.2003.12.005","DOI":"10.1016\/j.jcf.2003.12.005"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"119.        Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303(23):2386-2392. https:\/\/doi.org\/10.1001\/jama.2010.791","DOI":"10.1001\/jama.2010.791"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"120.        Hall H, Gadhok R, Alshafi K, Bilton D, Simmonds NJ. Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. Respir Med. 2015;109(3):357-363. https:\/\/doi.org\/10.1016\/j.rmed.2015.01.013","DOI":"10.1016\/j.rmed.2015.01.013"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"121.        Valli\u00e8res E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, et al. MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis. ERJ Open Res. 2016;2(1):00064-2015. https:\/\/doi.org\/10.1183\/23120541.00064-2015","DOI":"10.1183\/23120541.00064-2015"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"122.        Vanderhelst E, De Wachter E, Willekens J, Schuermans D, Vincken W, Malfroot A, et al. Increase in ventilated air spaces after eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. Acta Clin Belg. 2015;70(1):30-33. https:\/\/doi.org\/10.1179\/2295333714Y.0000000079","DOI":"10.1179\/2295333714y.0000000079"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"123.        Dolce D, Neri S, Grisotto L, Campana S, Ravenni N, Miselli F, et al. Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study. PLoS One. 2019;14(3):e0213497. https:\/\/doi.org\/10.1371\/journal.pone.0213497","DOI":"10.1371\/journal.pone.0213497"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"124.        Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect. 2004;56(3):208-214. https:\/\/doi.org\/10.1016\/j.jhin.2003.12.003","DOI":"10.1016\/j.jhin.2003.12.003"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"125.        Kappler M, Nagel F, Feilcke M, Kr\u00f6ner C, Pawlita I, Naehrig S, et al. Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study. Pediatr Pulmonol. 2016;51(10):1010-1019. https:\/\/doi.org\/10.1002\/ppul.23519","DOI":"10.1002\/ppul.23519"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"126.        Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, et al. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax. 2017;72(4):318-326. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-208949","DOI":"10.1136\/thoraxjnl-2016-208949"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"127.        Sol\u00eds A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. Pediatr Pulmonol. 2003;36(3):189-195. https:\/\/doi.org\/10.1002\/ppul.10231","DOI":"10.1002\/ppul.10231"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"128.        Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2021;3(3):CD001127. https:\/\/doi.org\/10.1002\/14651858.CD001127.pub5","DOI":"10.1002\/14651858.cd001127.pub5"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"129.        Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992;267(14):1947-1951. https:\/\/doi.org\/10.1001\/jama.1992.03480140073036","DOI":"10.1001\/jama.1992.03480140073036"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"130.        Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992;326(12):812-815. https:\/\/doi.org\/10.1056\/NEJM199203193261207","DOI":"10.1056\/nejm199203193261207"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"131.        Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J. 2011;37(4):806-812. https:\/\/doi.org\/10.1183\/09031936.00072510","DOI":"10.1183\/09031936.00072510"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"132.        Bakker EM, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas CJ, Hop WC, et al. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J. 2011;38(6):1328-1335. https:\/\/doi.org\/10.1183\/09031936.00006211","DOI":"10.1183\/09031936.00006211"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"133.        Barker M, Franke E, B\u00f6hle M, Pfannenstiel C, Heimann G. Effect of DNase on exercise capacity in cystic fibrosis. Pediatr Pulmonol. 2004;38(1):70-74. https:\/\/doi.org\/10.1002\/ppul.20048","DOI":"10.1002\/ppul.20048"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"134.        Bakker EM, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas CJ, Hop WC, Assael BM, Merkus PJ, Tiddens HA. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J. 2011 Dec;38(6):1328-35. https:\/\/doi.org\/10.1183\/09031936.00006211","DOI":"10.1183\/09031936.00006211"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"135.        B\u00f6llert FG, Paton JY, Marshall TG, Calvert J, Greening AP, Innes JA. Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group. Eur Respir J. 1999;13(1):107-113. https:\/\/doi.org\/10.1183\/09031936.99.13105399","DOI":"10.1183\/09031936.99.13105399"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"136.        Fiel SB, Fuchs HJ, Johnson C, Gonda I, Clark AR. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group. Chest. 1995;108(1):153-156. https:\/\/doi.org\/10.1378\/chest.108.1.153","DOI":"10.1378\/chest.108.1.153"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"137.        Frederiksen B, Pressler T, Hansen A, Koch C, H\u00f8iby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr. 2006;95(9):1070-1074. https:\/\/doi.org\/10.1080\/08035250600752466","DOI":"10.1080\/08035250600752466"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"138.        Furuya ME, Lezana-Fern\u00e1ndez JL, Vargas MH, Hern\u00e1ndez-Sierra JF, Ram\u00edrez-Figueroa JL. Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis. Arch Med Res. 2001;32(1):30-34. https:\/\/doi.org\/10.1016\/S0188-4409(00)00258-7","DOI":"10.1016\/s0188-4409(00)00258-7"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"139.        Heijerman HG, van Rossem RN, Bakker W. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients. Neth J Med. 1995;46(6):293-297. https:\/\/doi.org\/10.1016\/0300-2977(95)00022-F","DOI":"10.1016\/0300-2977(95)00022-f"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"140.        Hodson M. Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement [Article in French]. Arch Pediatr. 1995;2(7):679-681. https:\/\/doi.org\/10.1016\/0929-693X(96)81226-7","DOI":"10.1016\/0929-693X(96)81226-7"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"141.        McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest. 1996;110(4):889-895. https:\/\/doi.org\/10.1378\/chest.110.4.889","DOI":"10.1378\/chest.110.4.889"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"142.        Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax. 2010;65(1):51-56. https:\/\/doi.org\/10.1136\/thx.2009.116970","DOI":"10.1136\/thx.2009.116970"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"143.        Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139(6):813-820. https:\/\/doi.org\/10.1067\/mpd.2001.118570","DOI":"10.1067\/mpd.2001.118570"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"144.        Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, et al. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest. 2005;128(4):2327-2335. https:\/\/doi.org\/10.1378\/chest.128.4.2327","DOI":"10.1378\/chest.128.4.2327"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"145.        Robinson M, Hemming AL, Moriarty C, Eberl S, Bye PT. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol. 2000;30(1):16-24. https:\/\/doi.org\/10.1002\/1099-0496(200007)30:1<16::AID-PPUL4>3.0.CO;2-H","DOI":"10.1002\/1099-0496(200007)30:1<16::AID-PPUL4>3.0.CO;2-H"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"146.        Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax. 1996;51(2):119-125. https:\/\/doi.org\/10.1136\/thx.51.2.119","DOI":"10.1136\/thx.51.2.119"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"147.        Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001;358(9290):1316-1321. https:\/\/doi.org\/10.1016\/S0140-6736(01)06412-1","DOI":"10.1016\/s0140-6736(01)06412-1"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"148.        Bonestroo HJ, Slieker MG, Arets HG. No positive effect of rhdnase on the pulmonary colonization in children with cystic fibrosis. Monaldi Arch Chest Dis. 2010;73(1):12-17. https:\/\/doi.org\/10.4081\/monaldi.2010.308","DOI":"10.4081\/monaldi.2010.308"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"149.        Cobos N, Dan\u00e9s I, Gartner S, Gonz\u00e1lez M, Li\u00f1\u00e1n S, Arnau JM. DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group. Eur J Pediatr. 2000;159(3):176-181. https:\/\/doi.org\/10.1007\/s004310050046","DOI":"10.1007\/s004310050046"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"150.        Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol. 1997;23(4):243-248. https:\/\/doi.org\/10.1002\/(SICI)1099-0496(199704)23:4<243::AID-PPUL1>3.0.CO;2-N","DOI":"10.1002\/(SICI)1099-0496(199704)23:4<243::AID-PPUL1>3.0.CO;2-N"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"151.        Derelle J, Bertolo-Houriez E, Marchal F, Weber M, Virion JM, Vidailhet M. Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa [Article in French]. Arch Pediatr. 1998;5(4):371-377. https:\/\/doi.org\/10.1016\/S0929-693X(98)80022-5","DOI":"10.1016\/s0929-693x(98)80022-5"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"152.        Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, et al. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group. Pediatr Pulmonol. 1998;26(3):155-161. https:\/\/doi.org\/10.1002\/(SICI)1099-0496(199809)26:3<155::AID-PPUL1>3.0.CO;2-K","DOI":"10.1002\/(SICI)1099-0496(199809)26:3<155::AID-PPUL1>3.0.CO;2-K"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"153.        Hodson ME, McKenzie S, Harms HK, Koch C, Mastella G, Navarro J, et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2003;36(5):427-432. https:\/\/doi.org\/10.1002\/ppul.10348","DOI":"10.1002\/ppul.10348"},{"key":"ref153","doi-asserted-by":"publisher","unstructured":"154.        Johnson CA, Butler SM, Konstan MW, Breen TJ, Morgan WJ. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. J Pediatr. 1999;134(6):734-739. https:\/\/doi.org\/10.1016\/S0022-3476(99)70290-8","DOI":"10.1016\/s0022-3476(99)70290-8"},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"155.        Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol. 2011;46(6):545-553. https:\/\/doi.org\/10.1002\/ppul.21388","DOI":"10.1002\/ppul.21388"},{"key":"ref155","doi-asserted-by":"publisher","unstructured":"156.        Milla CE. Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax. 1998;53(12):1014-1017. https:\/\/doi.org\/10.1136\/thx.53.12.1014","DOI":"10.1136\/thx.53.12.1014"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"157.        Rozov T, de Oliveira VZ, Santana MA, Adde FV, Mendes RH, Paschoal IA, et al. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis--a one-year prospective study. Pediatr Pulmonol. 2010;45(9):874-882. https:\/\/doi.org\/10.1002\/ppul.21267","DOI":"10.1002\/ppul.21267"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"158.        Rozov T, Silva FA, Santana MA, Adde FV, Mendes RH; Brazilian Cystic Fibrosis Multicenter Study Group. A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study. Rev Paul Pediatr. 2013;31(4):420-430. https:\/\/doi.org\/10.1590\/S0103-05822013000400002","DOI":"10.1590\/s0103-05822013000400002"},{"key":"ref158","doi-asserted-by":"publisher","unstructured":"159.        Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D, et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration. 2001;68(2):160-164. https:\/\/doi.org\/10.1159\/000050486","DOI":"10.1159\/000050486"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"160.        Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med. 1995;89(7):499-502. https:\/\/doi.org\/10.1016\/0954-6111(95)90126-4","DOI":"10.1016\/0954-6111(95)90126-4"},{"key":"ref160","doi-asserted-by":"publisher","unstructured":"161.        Wizla-Derambure N, Michaud L, Sardet A, Deschildre A, Loeuille GA, Tassin E, et al. Effect of rhDNase on the respiratory function and nutritional status of children and adolescents with mucoviscidosis [Article in French]. Arch Pediatr. 1998;5(4):378-383. https:\/\/doi.org\/10.1016\/S0929-693X(98)80023-7","DOI":"10.1016\/s0929-693x(98)80023-7"},{"key":"ref161","doi-asserted-by":"publisher","unstructured":"162.        LiPuma JJ, Spilker T, Gill LH, Campbell PW 3rd, Liu L, Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med. 2001;164(1):92-96. https:\/\/doi.org\/10.1164\/ajrccm.164.1.2011153","DOI":"10.1164\/ajrccm.164.1.2011153"},{"key":"ref162","doi-asserted-by":"publisher","unstructured":"163.        Zlosnik JE, Zhou G, Brant R, Henry DA, Hird TJ, Mahenthiralingam E, et al. Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years\u2019 experience. Ann Am Thorac Soc. 2015;12(1):70-78. https:\/\/doi.org\/10.1513\/AnnalsATS.201408-395OC","DOI":"10.1513\/annalsats.201408-395oc"},{"key":"ref163","doi-asserted-by":"publisher","unstructured":"164.        Horsley A, Webb K, Bright-Thomas R, Govan J, Jones A. Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?. Front Cell Infect Microbiol. 2011;1:18. https:\/\/doi.org\/10.3389\/fcimb.2011.00018","DOI":"10.3389\/fcimb.2011.00018"},{"key":"ref164","doi-asserted-by":"publisher","unstructured":"165.        Tullis DE, Burns JL, Retsch-Bogart GZ, Bresnik M, Henig NR, Lewis SA, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros. 2014;13(3):296-305. https:\/\/doi.org\/10.1016\/j.jcf.2013.08.011","DOI":"10.1016\/j.jcf.2013.08.011"},{"key":"ref165","doi-asserted-by":"publisher","unstructured":"166.        Uluer AZ, Waltz DA, Kalish LA, Adams S, Gerard C, Ericson DA. Inhaled amilori-de and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cys-tic fibrosis. J Cyst Fibros. 2013;12(1):54-59. https:\/\/doi.org\/10.1016\/j.jcf.2012.06.006","DOI":"10.1016\/j.jcf.2012.06.006"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:52:15Z","timestamp":1683042735000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/3833\/en-US\/brazilian-guidelines-for-the-pharmacological-treatment-of-the-pulmonary-symptoms-of-cystic-fibrosis--official-document-of-the-sociedade-brasileira-de-"}},"subtitle":[],"editor":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-3327","authenticated-orcid":false,"given":"Carlos","family":"Antonio Riedi7","sequence":"additional","affiliation":[{"name":"7. Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba (PR) Brasil."}],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":166,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20230040","relation":{},"ISSN":["1806-3756"],"issn-type":[{"type":"electronic","value":"1806-3756"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}